Welcome to the September 2012 issue of Pharmaceutical Technology Sourcing and Management, Pharmaceutical Technology’s and Pharmaceutical Technology Europe’s information resource on pharmaceutical ingredients, manufacturing, and the supply chain. In this issue, we examine market opportunities for orphan drugs and recent US legislation for risk-based inspections of manufacturing facilities for generic APIs and finished dosage forms. Plus recent developments in parenteral drug delivery. And the latest developments from the bio/pharmaceutical industry relating to corporate social responsibility and sustainability.

APIs
Evaluating Market Opportunities in Orphan Drugs
Patricia Van Arnum, executive editor of Pharmaceutical Technology and Pharmaceutical Technology Europe and editor of Sourcing and Management
Although serving niche areas, orphan drugs offer good market opportunities for pharmaceutical companies and their suppliers.

Supply Chain
Moving to Risk-Based Inspections
Patricia Van Arnum, executive editor of Pharmaceutical Technology and Pharmaceutical Technology Europe and editor of Sourcing and Management
The Generic Drug User Fee Act seeks to improve regulatory activities, including achieving parity of inspections between foreign and domestic drug-manufacturing sites for both finished dosage forms and APIs of generic drugs.

Drug Delivery
Drug Delivery Insights: Injectable Drugs
Patricia Van Arnum, executive editor of Pharmaceutical Technology and Pharmaceutical Technology Europe and editor of Sourcing and Management
A roundup of the latest developments for drug delivery of parenteral drugs.

Outsourcing
Gauging Biopharm Outsourcing
Eric Langer, president of BioPlan Associates
Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.

Advertisement:

Osmotic Controlled Release Oral Delivery System
Event Date: September 19, 2012 at 11:00 AM EDT
Register Free at http://www.pharmtech.com/osmoticcontrolled

CSR and SUSTAINABILITY FORUM
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Using Microfluidic Chip Technology for Assessing Drug Quality
Patricia Van Arnum, executive editor of Pharmaceutical Technology and Pharmaceutical Technology Europe and editor of Sourcing and Management
A look at PharmaCheck, a field-based tool in development that uses microfluidic chip technology for assessing the quality of medicine in the developing world.